Adverum Biotechnologies to Present at BioCentury’s 24th Annual NewsMakers in the Biotech Industry Conference
Time: 10:30 –
A live and replay video webcast of the presentation will be available from Adverum’s website at http://investors.adverum.com.
Adverum is a gene therapy company advancing novel medicines that may offer life-changing benefits to patients living with serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, the Company generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with
Contacts for Adverum:
Charles ButlerVice President, Investor Relations & Corporate Communications 650-272-6260 firstname.lastname@example.org